ArticleGeburtshilfe und Frauenheilkunde2025
Induction of Labor with Oral Misoprostol - Effectiveness and Safety of Low-dose vs. High-dose Regimens.
Article in Geburtshilfe und Frauenheilkunde, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Safety of Two Different Oral Misoprostol Dosing Strategies for Labor Preinduction at Term: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Before the market launch of low-dose misoprostol (LDM) in the form of 25 µg tablets, high-dose misoprostol (HDM) was used off-label for labor induction in Germany. The differences between the effectiveness and safety of both dosage forms were investigated. Method: This retrospective cohort study included all pregnant women who were induced with misoprostol between 2019 and 2023. Until September 2021, misoprostol was available in the form of a 200 µg tablet which was divided manually and administered orally at an initial dose of 50 µg, followed by 100 µg every four hours. This was compared with the current administration regimen of an initial dose of 25 µg followed by 50 µg in terms of vaginal birth rate, duration of induction, and maternal and neonatal outcomes. Results: A total of 1941 patients were analyzed; 1397 received HDM and 544 received LDM. Vaginal delivery was achieved with equal frequency (87% HDM vs. 88% LDM, p = 0.95). The duration of induction was shorter in the HDM group (20.7 hours vs. LDM 22.7 hours, p = 0.028), and opioid requirements were higher (HDM 74% vs. LDM 69%, p = 0.036). Maternal complications and neonatal outcomes did not differ. Regression analysis found that high BMI was an independent factor for a failed first induction attempt (B 0.002, SEM 0.0004, p < 0.001). Conclusion: Both dosing regimens achieved high vaginal birth rates with comparable safety. Inductions with HDM were two hours shorter but were associated with higher opioid use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.